



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-1635-B)

In the Application of:

Andy Welcher, et al

Serial No.: 10/684,957

Filing Date: October 14, 2003

For: Human anti-IFN-gamma Neutralizing  
Antibodies as Selective IFN-gamma  
Pathway Inhibitors

Examiner: Kim, Y

Group Art Unit: 1644

Confirmation No. 8856

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:


Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. These references are listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned representative by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff LLP**

Date: January 26, 2006

  
Jason J. Derry, Ph.D.  
Reg. No. 50,692

|                                                                                                                          |                                                                                                                                                                                     |                                           |                                   |
|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|-----------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)<br> | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><br><b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br>(Use several sheets if necessary) | <b>Atty. Docket No.</b><br># 01-1635-B    | <b>Serial No.</b><br># 10/684,957 |
|                                                                                                                          |                                                                                                                                                                                     | <b>Applicant:</b><br>Andy Welcher, et al  |                                   |
|                                                                                                                          |                                                                                                                                                                                     | <b>Filing Date:</b><br># October 14, 2003 | <b>Group:</b><br># N/A            |

## U.S. PATENT DOCUMENTS

| Examiner Initial |    | Document Number | Date       | Name          | Class | Subclass | Filing Date if Appropriate |
|------------------|----|-----------------|------------|---------------|-------|----------|----------------------------|
|                  | 1. | 6,248,516       | 06/19/2001 | Winter, et al |       |          |                            |
|                  |    |                 |            |               |       |          |                            |

## FOREIGN PATENT DOCUMENTS

|  |  | Document Number | Date | Country | Class | Subclass | Translation |
|--|--|-----------------|------|---------|-------|----------|-------------|
|  |  |                 |      |         |       |          | No          |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

|  |    |                                                                                                                                                                                                                                                 |
|--|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | 2. | Barbas et al., "Human autoantibody recognition of DNA", Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2529-33                                                                                                                                     |
|  | 3. | Beiboer et al., "Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent", J Mol Biol. 2000 Feb 25;296(3):833-49. |
|  | 4. | Desiderio A et al., "A semi-synthetic Repertoire of Intrinsically Stable Antibody Fragments Derived from a Single-framework Scaffold", <i>J. Mol. Biol.</i> 2001; 310, 603-615                                                                  |
|  | 5. | Desmyter A, et al., "Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody", <i>The Journal of Biological Chemistry</i> 2001; Vol. 276, No. 28, pp. 26285-26290                           |
|  | 6. | Ditzel et al., "Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection", J Immunol. 1996 Jul 15;157(2):739-49                                                                                     |

|          |                 |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

|     |                                                                                                                                                                                                                                         |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 7.  | Kabat EA et al., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, Fifth Edition, NIH Publication No. 91-3242                                                                                                                            |
| 8.  | Klimka et al., "Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning", Br J Cancer. 2000 Jul;83(2):252-60                                                                                       |
| 9.  | Hasemann CA and Capra JD, "Immunoglobulins: Structure and Function", FUNDAMENTAL IMMUNOLOGY, Third Edition 1993 pp. 288-292                                                                                                             |
| 10. | Rader et al., "A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries", Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8910-5                                                                  |
| 11. | Sandborn WJ and Targan SR, "Biologic Therapy of Inflammatory Bowel Disease", <i>Gastroenterology</i> 2001; 122:1592-1608                                                                                                                |
| 12. | Schier R, et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-Chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site", <i>J. Mol. Biol.</i> 1996; 263, 551-567 |
| 13. | Skurkovich B and Skurkovich S, "Anti-interferon- $\gamma$ antibodies in the treatment of autoimmune diseases", <i>Current Opinion in Molecular Therapeutics</i> , 2003, 5(1):52-57                                                      |
| 14. | Xu JL and Davis MM, "Diversity in the CDR3 Region of V <sub>H</sub> Is Sufficient for Most Antibody Specificities", <i>Immunity</i> , July, 2000, Vol. 13, 37-45                                                                        |
| 15. | Yang WP, et al., "CDR Waling Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range", <i>J. Mol. Biol.</i> 1995; 254, 392-403                                                           |
|     |                                                                                                                                                                                                                                         |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.